Home Diagnostics, Inc. v. J&J Lifescan
This article was originally published in The Gray Sheet
Executive Summary
U.S. Court of Appeals for the Federal Circuit in Washington, D.C. rules that Home Diagnostics' Prestige glucose monitor did not infringe on patents held by Johnson & Johnson subsidiary Lifescan. April 6 decision upholds earlier finding by U.S. District Court in Wilmington, Delaware. Home Diagnostics pulled the Prestige product from the market in November 1999 and has since introduced the Prestige LX, which uses a significantly different technology from the earlier version, the firm says (1"The Gray Sheet" July 3, 2000, p. 17)
You may also be interested in...
J&J Hopes To Win Back Prestige Case After Judge Favors Home Diagnostics
Johnson & Johnson's LifeScan subsidiary plans to appeal a June 21 ruling by a Delaware district court that Home Diagnostics Inc.' s Prestige blood glucose test system does not infringe J&J patents.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.